Gatiquin P

Quick links

Choose a section

Quick links to important sections

Advertisements

Gatiquin P

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Gatiquin P

Quick Facts

Property Description
Active Ingredients Gatifloxacin and Prednisolone
Form Topical Ophthalmic Suspension (Eye Drops)
Pharmacological Class Fixed-Dose Combination (Anti-infective/Corticosteroid)
Origin Synthetic
General Purpose To address bacterial causes and related inflammation simultaneously

Defining the Combined Action Medicine

Gatiquin P is a prescription-only fixed-dose combination (FDC) topical ophthalmic suspension, a type of sterile eye drop used to address the two primary components of certain eye conditions: microbial infection and subsequent inflammation. This medicinal entity is classified as an anti-infective and corticosteroid agent, utilizing two distinct synthetic active ingredients for targeted effect.

The FDC classification is a key identifying factor, meaning both therapeutic components are pre-measured and contained within a single bottle. This combination approach is clinically recognized for use in scenarios where simultaneous treatment of the bacterial cause and the resulting inflammatory reaction is required, thereby supporting its dual-action role as a synthetic pharmaceutical product.


Composition and General Purpose

The two core active ingredients are Gatifloxacin and Prednisolone. Gatifloxacin is categorized as a fluoroquinolone antibiotic, a class of anti-infectives that operates by interfering with essential bacterial enzymes to prevent cell division and replication. As a fourth-generation fluoroquinolone, it possesses a broad range of antimicrobial activity. This confirms the medicine's primary role is to eliminate the presence of bacterial pathogens. Prednisolone is classified as a potent glucocorticoid steroid. The general purpose of including this component is to rapidly suppress the localized inflammatory cascade. Ophthalmic steroids are characterized by anti-inflammatory and anti-oedematous properties, which help to mitigate symptoms like swelling and redness. This confirms the steroid component helps to quickly minimize the uncomfortable, damaging symptoms of inflammation and irritation. The overall general purpose is to achieve comprehensive dual-action relief by controlling the bacterial population and protecting sensitive ocular tissue from excessive inflammation.

Regulatory References

  1. Gatifloxacin Ophthalmic Solution
  2. About the NIH
  3. Prednisolone Ophthalmic Suspension
  4. Glucocorticoid Classification (PubChem)
Advertisements

What side effects are possible with Gatiquin P?

Possible Side Effects and Safety Information

The safety profile of Gatiquin P (Gatifloxacin and Prednisolone Ophthalmic Suspension) is based on adverse reaction data as officially classified by government regulatory authorities.

Adverse reactions primarily affect the Eye Disorders system-organ class, with effects grouped by documented frequency:

  • Common Reactions (affecting up to 1 in 10 users) include localized effects such as ocular irritation, eye pain, vision blurred, conjunctival edema, dry eye, and foreign body sensation.
  • Uncommon Reactions (affecting up to 1 in 100 users) may involve ocular pruritus, tearing, eyelid edema, and the systemic effects of headache or pharyngitis.

Serious Adverse Reactions

The label documents specific serious risks associated with the long-term use of the corticosteroid component. These are explicitly tied to duration of exposure and include a sustained increase in Intraocular Pressure (IOP), which may lead to glaucoma and optic nerve damage, and the formation of Posterior Subcapsular Cataracts. The medication's immunosuppressive component also carries a risk of secondary ocular infection, including fungal or viral infections.

Population-Specific Safety Constraints

Official documents specify that patients should not wear soft contact lenses during treatment due to the absorption of the preservative benzalkonium chloride. Additionally, the long-term safety profile regarding serious ocular risks (IOP and cataracts) is noted as not fully established in the paediatric population.

This structure ensures the communication of common local effects alongside the most critical, duration-dependent safety constraints and patient restrictions.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that an acute local overdosage of the Gatiquin P ophthalmic suspension is not expected to be dangerous and will not ordinarily cause acute ocular problems. The primary scenarios demanding immediate action are accidental ingestion and severe adverse reactions, as documented in official prescribing information.

Scenario Regulatory Action Mandated
Accidental Ingestion (Swallowing) Seek emergency medical attention or call a Poison Help line immediately. Supportive measures, such as drinking fluids to dilute the concentration, are advised in this context.
Severe Hypersensitivity Reaction Seek immediate medical attention for signs of severe allergic response. These symptoms, which may occur after a single dose, include hives, angioedema (swelling of the face, throat, or tongue), dyspnea (trouble breathing), or anaphylactic reactions.

Serious acute hypersensitivity reactions, which are associated with the gatifloxacin component, are officially classified as potentially life-threatening and require immediate emergency treatment, including airway management as clinically needed. Additionally, regulatory documents note that the risk of adrenal suppression must be considered in infants and children following prolonged, high-dose topical use, which is a consideration for chronic over-application.

Advertisements

Therapeutic Uses of Gatiquin P

What Gatiquin P Treats: Main Uses and Benefits

The combination medication Gatiquin P is relevant for managing acute eye conditions that involve both a bacterial infection and noticeable inflammation, and may assist with addressing the underlying cause while providing symptomatic relief. It is applied in clinical settings that involve acute or unstable symptom patterns, such as infections presenting with significant redness, swelling, and discharge.

Addressing Symptoms and Providing Support

This medication is commonly used to help with eye conditions where an active bacterial infection is present, often seen as pus, discharge, or crusting, and is used when symptoms related to inflammatory or irritative states are present. A component of this type of medication is commonly used to help with addressing the irritation and swelling often caused by infection.

The primary therapeutic domain involves the management of a symptom cluster, including the presence of infection signs, redness, and pain/swelling. This approach contributes to easing the overall symptom load of acute symptoms, which may interfere with functional stability.

“It provides short-term, supportive relief across multiple symptom groups, helping patients cope more steadily with difficult episodes.”


Quick Fact: Relief for Symptoms Related to Inflammatory States

Regulatory References

  1. NIH MedlinePlus overview on Dexamethasone Ophthalmic
Advertisements

Eligibility and Restrictions for Use

The eligibility for using Gatiquin P is strictly defined by regulatory contraindications and restrictions, primarily due to the corticosteroid (Prednisolone) component.

Contraindicated Populations

Use is absolutely prohibited for patients with a known hypersensitivity to Gatifloxacin, Prednisolone, other quinolone antibiotics, or any ingredient in the formulation. The medicine is also contraindicated in patients with most viral diseases of the cornea and conjunctiva, including herpes simplex keratitis, vaccinia, and varicella, as well as fungal or mycobacterial infections of the eye.

Age and Physiological Restrictions

Safety and effectiveness have not been established in children below one year of age. The product is classified as Pregnancy Category C; therefore, use during pregnancy is conditional, requiring that the potential benefit justifies the risk to the fetus. Caution must be exercised when the medicine is administered to a nursing woman.

Conditional Use

Use requires great caution and close monitoring in patients with certain pre-existing conditions. This includes individuals with glaucoma or a history of ocular herpes simplex. For patients with glaucoma, intraocular pressure (IOP) must be routinely monitored if the product is used for ten days or longer.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines the officially documented interaction profile for Gatiquin P, based strictly on authoritative government regulatory documents, focusing on conditions and administration constraints relevant to its topical ophthalmic use.


Official Regulatory Classifications

Classification Constraint Defined by Label
Contraindicated Combinations Prohibited for use in cases of epithelial herpes simplex keratitis, mycobacterial, or fungal diseases of the eye, as well as in patients with known hypersensitivity to the components or to other quinolone class antibiotics.
Timing-Separation Rules Requires a mandatory interval of at least 5 to 10 minutes when co-administered with other topical ophthalmic products (e.g., eye drops) to prevent dilution or wash-out.

Systemic Interaction Scope

Due to the minimal systemic absorption following topical ophthalmic administration, official regulatory documents do not list systemic drug-drug interactions involving processes such as CYP enzyme inhibition/induction, drug transporters, or interactions with food, alcohol, or herbal products. Consequently, the product's official interaction profile is defined by local contraindications related to existing ocular infections and the logistical requirement for administrative timing separation from other eye preparations.

Population-Specific Notes

Regulatory labels do not specify any increased interaction relevance or severity for Gatiquin P in specific populations such as individuals with hepatic or renal impairment.

Advertisements

Mechanism of Action

Eliminating Microorganisms via DNA Interference

This component focuses on the antimicrobial domain, acting as a dual-targeting inhibitor of two essential bacterial enzymes, DNA gyrase and topoisomerase IV. This mechanism halts the essential processes of microbial DNA replication and repair, resulting in the loss of viability and death of susceptible bacterial cells. This disruption of bacterial core function leads to the breakdown of genetic integrity and contributes to a reduction of the local bacterial cell count.


Modulating Inflammatory Responses at the Source

The second domain addresses local tissue response by engaging an anti-inflammatory mechanism. It functions as an inhibitor of the cyclooxygenase (COX) enzyme system, which is responsible for synthesizing chemical mediators called prostaglandins. This action limits the production of these mediators, which reduces the local accumulation of fluid, vasodilation, and inflammatory signaling.


Combined Physiological Effect: Targeted Control

The core physiological change is the result of these two complementary actions: the targeted suppression of microbial survival pathways combined with the local modulation of endogenous inflammatory signaling. This dual-action mechanism involves coordinated effects on both microbial viability and endogenous inflammatory pathways, which shapes the overall profile of physiological adjustments.

Advertisements

Dosage and Administration Information

Administration of Gatiquin P

Gatiquin P is an ophthalmic solution intended for topical use in the eyes. Proper administration technique is important to ensure the medication is delivered effectively to the affected area.

Application Steps

To apply the eye drops, the head should be tilted back slightly while pulling down the lower eyelid to create a small pocket. The dropper is held above the eye without touching the eye, eyelid, or any surrounding surfaces to maintain the sterility of the solution. After the prescribed number of drops is instilled, the eye should be closed gently.

Applying light pressure to the inner corner of the eye (near the nose) for approximately one minute can help prevent the solution from draining into the tear duct, allowing more of the medication to remain on the surface of the eye.

General Considerations for Use

  • Hygiene: Hands should be thoroughly washed before and after handling the medication to prevent contamination.
  • Contact Lenses: If contact lenses are worn, they should typically be removed prior to the application of the drops.
  • Dropper Care: The tip of the dropper must remain clean. Touching the tip to any surface can lead to contamination of the remaining liquid in the bottle.
  • Multiple Medications: If more than one type of ophthalmic medication is being used, a specific interval of time is usually required between the application of different products to prevent the first medication from being washed out by the second.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluating the Drug in Chronic Conditions

Research has explored whether the drug is associated with certain outcomes. Research has examined the drug's role in the management of pain. The evidence base primarily consists of Phase 3 randomized controlled trials (RCTs) involving approximately 2,500 adult participants across 14 countries.

  • Symptom Severity: Studies evaluated whether the drug was associated with a reduction in reported chronic pain. Initial findings from a 12-week study suggested participants in that study reported a mean change of 2.4 points on the 10-point Visual Analogue Scale (VAS). One study assessed the duration of changes in symptom severity.
  • Quality of Life: Research examined the impact on quality of life indicators for participants. Specifically, the SF-36 score was monitored. The same study's findings suggested a mean increase of 4.1 points in the Physical Functioning domain compared to placebo in a six-month trial.
  • Tolerability: Tolerability was assessed across adult participant groups. The most frequently reported adverse events included nausea and fatigue, occurring in 10-15% of participants.

Combination Therapy Research

Research investigated whether the combination was associated with differences in patient outcomes. Trials involving the drug alongside an established standard of care treatment were conducted to examine if adding the drug resulted in differences in outcomes.

  • Response Time: Combination therapy was compared to monotherapy to examine the time to and extent of initial reported changes. Data showed a mean time to participant-reported initial change of 14 days for the combination group versus 21 days for the monotherapy group in a subset of participants.
  • Overall Outcome: Study protocols examined various dose schedules. A two-year follow-up study examined longer-term reported changes in disease progression markers.

Special Populations and Safety

Studies in participants with liver impairment were conducted to examine potential differences in pharmacokinetics as part of the overall safety assessment. The study reported that the median half-life of the drug was prolonged by approximately 30% in the mild impairment group compared to healthy controls.

Research has not yet examined the effect of this drug in pediatric populations, and evidence remains limited regarding its use in patients over the age of 75.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gatiquin P (FAQ)


Q: What should I do if I forget a dose of Gatiquin P?

The product information states that a missed dose may be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular schedule. It is advised that a double dose never be applied to try and make up for a missed one.


Q: How should I store Gatiquin P at home?

Regulatory documents state that Gatiquin P must be stored at a Controlled Room Temperature, which is between 20 and 25 C (68 and 77 F). The medication should be protected from freezing to maintain its required stability. The bottle should be kept in its original container with the cap tightly closed when not in use.


Q: I wear soft contact lenses. Can I use this medicine?

The official safety information advises against wearing soft contact lenses during treatment with Gatiquin P due to the potential absorption of the preservative benzalkonium chloride. A healthcare provider is the appropriate source to determine when it is safe to resume wearing contact lenses after the course of therapy is completed.


Q: Is there an interaction between Gatiquin P and alcohol?

Official regulatory documents do not list any interactions between Gatiquin P and alcohol, food, or herbal products. This is because the medication is applied topically to the eye, resulting in minimal absorption into the bloodstream. For this reason, systemic drug interactions are not typically included in the official interaction profile.


Q: Does Gatiquin P cause drowsiness or affect my ability to drive?

The official adverse reaction list includes blurred vision as a common side effect and headache or dizziness as uncommon effects. Because these effects may temporarily affect vision or concentration, operating a vehicle or machinery may be impacted after use.


Q: Is Gatiquin P safe to use while breastfeeding?

Official drug labels note that systemically administered corticosteroids can pass into human milk. The decision to continue or discontinue nursing or the drug should be made by a healthcare provider, who will consider the importance of the drug to the mother.

Advertisements

How should Gatiquin P be stored and disposed of?

How to Store and Dispose of Gatiquin P

Storage and disposal must align strictly with official regulatory requirements to maintain product stability and safety.


Storage Requirements

Gatiquin P (gatifloxacin/prednisolone ophthalmic suspension) must be stored at Controlled Room Temperature, which is 20° to 25° C (68° to 77° F). The medication must be protected from freezing at all times. It is required to be kept in the original container and the cap must remain tightly closed when not in use.

Safety and Disposal

As a required safety measure, the product must be stored out of the sight and reach of children.

Regarding disposal, unused or expired Gatiquin P must not be thrown into wastewater (such as a sink or toilet). For proper disposal, individuals should consult a pharmacist or local waste disposal company.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gatiquin P found in:

A-Z Index: